EFSA published a report (7902) on the outcome of the consultation with the Member States on the possible approval of magnesium hydroxide E 528 as a basic substance.
On 31.01.2023 EFSA published its conclusion on the peer review of ethephon.
EFSA published on 07.11.2022 its conclusion on the peer review of Cydia pomonella granulovirus (CpGV).
EFSA published on 17.110.2022 its conclusions on the confirmatory data on ED properties of flutianil.
On 29.09.2022 EFSA published its conclusions on the peer review of rimsulfuron.
EFSA published on 29.09.2022 (another) conclusion on benfluralin.
EFSA published a new conclusion on the peer review of abamectin.
EFSA published its conclusion on the peer review of isoflucypram.
On 20.05.2022 EFSA published its conclusion on the peer review of limestone (powder) (calcium carbonate).
EFSA published its opinion on the peer review of Purpureocillium lilacinum strain PL11.
EFSA published on 18.05.2022 its conclusion on the peer review of oxamyl.
EFSA published its conclusion on the peer review of triflusulfuron-methyl.
EFSA published on 13.05.2022 its conclusion on the peer review of aluminium ammonium sulphate.
On 07.04.2022 EFSXA published its conclusion on the peer review of Trichoderma atroviride strain AT10
EFSA published on 31.03.2022 its conclusion on the peer review of Aspergillus flavus strain MUCL54911.
EFSA published on 28.03.2022 its conclusion on the peer review of the assessment of heptamaloxyglucan.
EFSA published on 28.03.2022 its conclusion on confirmatory data submitted for thiabendazole.
EFSA published on 28.03.2022 its conclusion on the peer review of Trichoderma atroviride strain AGR2.
EFSA published on 04.02.2022 its conclusions on confirmatory data for propyzamide.
EFSA published on 27.01.2022 a conclusion on the peer review of another repellent: fish oil.